PROSPECTUS SUPPLEMENT
(To prospectus dated November 7, 2019)
$1,700,000,000
Westlake Chemical Corporation
$300,000,000 0.875% Senior Notes due 2024
$350,000,000 2.875% Senior Notes due 2041
$600,000,000 3.125% Senior Notes due 2051
$450,000,000 3.375% Senior Notes due 2061
We are offering $300,000,000
aggregate principal amount of our 0.875% Senior Notes due 2024 (the 2024 notes), $350,000,000 aggregate principal amount of our 2.875% Senior Notes due 2041 (the 2041 notes), $600,000,000 aggregate principal amount of our
3.125% Senior Notes due 2051 (the 2051 notes) and $450,000,000 aggregate principal amount of our 3.375% Senior Notes due 2061 (the 2061 notes and, together with the 2024 notes, the 2041 notes and the 2051 notes, the
notes).
The 2024 notes will mature on August 15, 2024, the 2041 notes will mature on August 15, 2041, the 2051 notes will mature on August 15,
2051 and the 2061 notes will mature on August 15, 2061. The 2024 notes will accrue interest at a rate of 0.875% per annum, the 2041 notes will accrue interest at a rate of 2.875% per annum, the 2051 notes will accrue interest at a rate of 3.125% per
annum and the 2061 notes will accrue interest at a rate of 3.375% per annum. Interest on each series of the notes will accrue from August 19, 2021 and will be payable semi-annually in arrears on February 15 and August 15 of each year, beginning
February 15, 2022.
We may redeem the 2024 notes at our option, in whole or in part, at any time on or after August 15, 2022 at a redemption price equal to
100% of the principal amount of the 2024 notes being redeemed, plus accrued and unpaid interest, if any, to, but not including, the redemption date. We may redeem the 2041 notes, the 2051 notes and the 2061 notes at our option, in whole or in part,
at any time prior to their maturity at the applicable redemption price described under Description of the Senior NotesOptional Redemption. If a change of control triggering event as described under Description of the Senior
NotesChange of Control Triggering Event occurs, we will be required, unless we have exercised our right to redeem each such series of the notes, to offer to purchase the notes of each such series from the holders.
We intend to use the net proceeds from this offering to fund a portion of the purchase price of our pending Acquisitions (as defined herein) and to pay related
fees and expenses. See SummaryAbout Westlake Chemical CorporationRecent Developments and Use of Proceeds. This offering is not contingent upon the consummation of any of the Acquisitions. However, if we do not
consummate an Acquisition under specified circumstances, we will be required to redeem all of the outstanding (i) 2041 notes in the case of the LASCO Acquisition (as defined herein) and (ii) 2051 notes and 2061 notes in the case of the Boral
Acquisition (as defined herein), in each case at a redemption price equal to 101% of the principal amount of the notes of such series being redeemed, plus accrued and unpaid interest, if any, to, but not including, the date of such special mandatory
redemption as described under Description of the Senior NotesSpecial Mandatory Redemption.
The notes will be our senior unsecured
obligations and will rank equally in right of payment with all of our other senior unsecured indebtedness from time to time outstanding. The notes will be effectively subordinated to any secured indebtedness to the extent of the value of the assets
securing such indebtedness and to the indebtedness and other liabilities of our subsidiaries.
The notes will be issued only in registered form in minimum
denominations of $2,000 and integral multiples of $1,000 in excess thereof in book-entry form only.
Investing in the notes
involves risks. See Risk Factors beginning on page S-16 of this prospectus supplement, as well as the risks set forth in our filings with the Securities and
Exchange Commission that are incorporated by reference into this prospectus supplement, to read about important factors you should consider carefully before investing in the notes.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Per 2024
Note
|
|
|
Total
|
|
|
Per 2041
Note
|
|
|
Total
|
|
|
Per 2051
Note
|
|
|
Total
|
|
|
Per 2061
Note
|
|
|
Total
|
|
Public offering price (1)
|
|
|
99.853
|
%
|
|
$
|
299,559,000
|
|
|
|
97.969
|
%
|
|
$
|
342,891,500
|
|
|
|
97.261
|
%
|
|
$
|
583,566,000
|
|
|
|
96.922
|
%
|
|
$
|
436,149,000
|
|
Underwriting discount
|
|
|
0.450
|
%
|
|
$
|
1,350,000
|
|
|
|
0.875
|
%
|
|
$
|
3,062,500
|
|
|
|
0.875
|
%
|
|
$
|
5,250,000
|
|
|
|
0.875
|
%
|
|
$
|
3,937,500
|
|
Proceeds, before expenses, to us (1)
|
|
|
99.403
|
%
|
|
$
|
298,209,000
|
|
|
|
97.094
|
%
|
|
$
|
339,829,000
|
|
|
|
96.386
|
%
|
|
$
|
578,316,000
|
|
|
|
96.047
|
%
|
|
$
|
432,211,500
|
|
(1)
|
Plus accrued interest, if any, from August 19, 2021, if settlement occurs after that date.
|
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
We do not intend to apply for listing of the notes of any series on any securities exchange or for inclusion of the notes of any series on any automated dealer
quotation system. We expect that delivery of the notes, in book-entry form only through the facilities of The Depository Trust Company for the accounts of its participants, including Euroclear Bank S.A./N.V., as operator of the Euroclear System, and
Clearstream Banking, société anonyme, will be made on or about August 19, 2021.
Joint
Book-Running Managers
|
|
|
|
|
Deutsche Bank Securities
|
|
BofA Securities
|
|
Citigroup
|
|
|
|
|
|
|
|
|
|
J.P. Morgan
|
|
Wells Fargo Securities
|
|
|
|
|
|
|
|
PNC Capital Markets LLC
|
|
Goldman Sachs & Co. LLC
|
|
RBC Capital Markets
|
Co-Managers
|
|
|
|
|
|
|
BMO Capital Markets
|
|
Capital One Securities
|
|
Truist Securities
|
|
UBS Investment Bank
|
The date of this prospectus supplement is August 5, 2021